Literature DB >> 15109224

The outback catheter: a new device for true lumen re-entry after dissection during recanalization of arterial occlusions.

Klaus A Hausegger1, Borjana Georgieva, Horst Portugaller, Josef Tauss, Gerhard Stark.   

Abstract

PURPOSE: To report the initial experience with a new catheter system (The Outback catheter) designed to allow fluoroscopically controlled re-entry of the true arterial lumen after subintimal guidewire passage during recanalization procedures of arterial occlusions.
METHODS: The catheter was used in 10 patients with intermittent claudication caused by chronic segmental occlusions of the superficial femoral or popliteal arteries. In all patients, conventional guidewire recanalization had failed.
RESULTS: In 8 patients, successful true lumen re-entry was achieved with the Outback catheter. Percutaneous transluminal angioplasty was successfully performed in these patients without complications. Two technical failures occurred in heavily calcified arteries.
CONCLUSION: The Outback catheter was safe and effective when used in complicated recanalization procedures in the superficial femoral and popliteal artery and the tibial trunk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15109224     DOI: 10.1007/s00270-003-0025-x

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  12 in total

1.  Hydrodynamic boost: a novel re-entry technique in subintimal angioplasty of below-the-knee vessels.

Authors:  Roberto Ferraresi; Meneme Hamade; Vito Gallicchio; Nicola Troisi; Giovanni Mauri
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

Review 2.  [Subintimal recanalization. Indications, technique and results].

Authors:  B Radeleff; M Sumkauskaite; N Kortes; D Gnutzmann; T Mokry; H U Kauczor; U Stampfl
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

3.  Subintimal angioplasty in the treatment of chronic lower limb ischemia.

Authors:  Sung Ki Cho; Young Soo Do; Sung Wook Shin; Kwang Bo Park; Dong-Ik Kim; Young Wook Kim; Duk-Kyung Kim; Sung Wook Choo; In Wook Choo
Journal:  Korean J Radiol       Date:  2006 Apr-Jun       Impact factor: 3.500

4.  Re-entry devices in the treatment of peripheral chronic occlusions.

Authors:  Marcus Smith; Reji Pappy; Thomas A Hennebry
Journal:  Tex Heart Inst J       Date:  2011

5.  Strategies for successful percutaneous revascularization of chronic total occlusion of the femoropopliteal arteries when the antegrade passage of a guide wire fails.

Authors:  Hui Jin Lee; Sang Woo Park; Il Soo Chang; Hae Jeong Jeon; Jeong Hee Park
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

6.  Transpopliteal balloon-assisted excimer-laser atherectomy for the treatment of chronic femoropopliteal occlusions: feasibility and initial results.

Authors:  Christopher W Lüdtke; Fabian Scheer; Peter Kamusella; Christian Wissgott; Reimer Andresen
Journal:  Clin Med Insights Cardiol       Date:  2015-02-24

7.  The open retrograde approach as an alternative for failed percutaneous access for difficult below the knee chronic total occlusions-A case series.

Authors:  K Saravana; Y K Tan; S Kum; T Y Tang
Journal:  Int J Surg Case Rep       Date:  2015-09-24

8.  Outcomes of endovascular treatment for patients with TASC II D femoropopliteal occlusive disease: a single center study.

Authors:  Xiangjiang Guo; Guanhua Xue; Xiaozhong Huang; Hui Xie; Wei Liang; Jiwei Zhang; Feng Lin; Tianping Yao
Journal:  BMC Cardiovasc Disord       Date:  2015-05-29       Impact factor: 2.298

9.  Endovascular sharp recanalization for calcified femoropopliteal artery occlusion.

Authors:  Hsuan-Li Huang; Hsin-Hua Chou; Tien-Yu Wu
Journal:  Case Rep Cardiol       Date:  2012-09-02

10.  Retrograde distal superficial femoral artery approach in the supine position for chronic superficial femoral artery occlusion.

Authors:  Sanghoon Shin; Seunghwan Kim; Young-Guk Ko; Myeung-Ki Hong; Yangsoo Jang; Donghoon Choi
Journal:  Korean Circ J       Date:  2014-05-20       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.